6-吡咯烷-1-基-7H-嘌呤 | 1928-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6-吡咯烷-1-基-7H-嘌呤
• 英文名称: 6-(pyrrolidin-1-yl)-9H-purine
• 英文别名: 6-pyrrolidin-1-yl-7H-purine
• CAS: 1928-89-8
• 化学式: C₉H₁₁N₅
• mdl: MFCD02172429
• 分子量: 189.22
• InChiKey: IQSRNEOAVVBNGN-UHFFFAOYSA-N

物化性质

• 熔点：
  352 °C
• 沸点：
  304.3±52.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  57.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-吡咯烷-1-基-7H-嘌呤 在 溴 、 sodium acetate 作用下， 以 溶剂黄146 为溶剂， 反应 3.0h， 以98%的产率得到8-bromo-6-pyrrolidin-1-yl-9H-purine
  参考文献：
  名称：

  闭环易位合成稠合二氢吡啶并[ e ]嘌呤

  摘要：

  8，9-二烯丙基尿烷或9-丁烯基-8-乙烯基嘌呤与Grubbs第二代催化剂的闭环易位（RCM）分别产生了稠合的6,9-或8,9-二氢吡啶并[ e ]嘌呤。在9-烯基化之后，由8-溴嘌呤制备8，9-二烯基嘌呤，随后在Pd（PPh 3）4或Pd（PPh 3）2 Cl 2的存在下，在C-8将Stille偶联与烯基锡烷。

  DOI：

  10.1016/j.tetlet.2010.10.008
• 作为产物：
  描述：

  6-甲巯基嘌呤 在 三氯异氰尿酸 作用下， 以 甲醇 、 水 、 正丁醇 为溶剂， 反应 1.75h， 生成 6-吡咯烷-1-基-7H-嘌呤
  参考文献：
  名称：

  Villar, Jose Daniel Figueroa; Motta, Marita Almeida, Nucleosides, nucleotides and nucleic acids, 2000, vol. 19, # 5-6, p. 1005 - 1015

  摘要：

  DOI：

文献信息

• Synthesis of Chiral Cyclopropyl Carbocyclic Purine Nucleosides<i>via</i>Asymmetric Intramolecular Cyclopropanations Catalyzed by a Chiral Ruthenium(II) Complex
  作者：Ke-Xin Huang、Ming-Sheng Xie、Guo-Feng Zhao、Gui-Rong Qu、Hai-Ming Guo

  DOI：10.1002/adsc.201600377

  日期：2016.11.17

  The synthesis of chiral cyclopropyl carbocyclic purine nucleoside analogues via the highly enantioselective intramolecular cyclopropanation reactions has been reported. With a chiral ruthenium(II)‐phenyloxazoline complex as the catalyst, cyclopropyl carbocyclic purine nucleoside analogues containing three contiguous stereocenters were obtained with up to 99% yield and 99% ee. Furthermore, a chiral

  已经报道了通过高度对映选择性分子内环丙烷化反应合成手性环丙基碳环嘌呤核苷类似物。以手性钌（II）-苯基恶唑啉配合物为催化剂，可得到含三个连续立体中心的环丙基碳环嘌呤核苷类似物，收率高达99％，ee高达99％。此外，使用该策略可以简明方式合成具有抗BLV活性的手性环丙基碳环腺苷核苷。
• The Enantioselective Synthesis of Chiral Carbocyclic Nucleosides via Palladium‐Catalyzed Asymmetric Allylic Amination of Alicyclic MBH Adducts with Purines
  作者：Bo Kang、Qi‐Ying Zhang、Gui‐Rong Qu、Hai‐Ming Guo

  DOI：10.1002/adsc.202000088

  日期：2020.5.12

  The enantioselective synthesis of carbocyclic nucleosides through the palladium‐catalyzed asymmetric allylic amination of alicyclic Morita‐Baylis‐Hillman (MBH) adducts with purines was successfully developed. With a combination of Pd2(dba)3/L7 as catalyst, various optically active carbocyclic nucleosides featuring a C=C double bond in the carbocycle moiety were obtained in high yields (up to 97%) with

  通过钯催化的嘌呤与脂环式森田-贝利斯-希尔曼（MBH）加合物的钯催化不对称烯丙基胺化，成功开发了碳环核苷的对映选择性合成。结合使用Pd 2（dba）3 / L7作为催化剂，可以以高收率（高达97％）和优异的N 9 / N 7-获得各种在碳环部分具有C = C双键的旋光碳环核苷。选择性（> 95/5）和对映选择性（> 99.6％）。另外，这些核苷类似物允许快速转化为多种其他有趣的结构上不同的手性碳环核苷。
• Synthesis and Cytostatic Activity of N-[2-(Phosphonomethoxy)alkyl] Derivatives of N6-Substituted Adenines, 2,6-Diaminopurines and Related Compounds
  作者：Antonín Holý、Ivan Votruba、Eva Tloušťová、Milena Masojídková

  DOI：10.1135/cccc20011545

  日期：——

  N⁶-Substituted adenine and 2,6-diaminopurine derivatives of 9-[2-(phosphonomethoxy)- ethyl] (PME), 9-[(R)-2-(phosphonomethoxy)propyl] [(R)-PMP] and enantiomeric (S)-PMP series were synthesized by reactions of primary or secondary amines with 6-chloro-9-[2-(diisopropoxyphosphoryl)methoxy]alkyl}purines (26-28) or 2-amino-6-chloro-9-[2-(diisopropoxy- phosphoryl)methoxy]alkyl}purines (29-31) followed by treatment of the diester intermediates32with bromo(trimethyl)silane and hydrolysis. Diesters32were also obtained by reaction ofN⁶-substituted purines with synthons23-25bearing diisopropoxyphosphoryl group. Alkylation of 2-amino-6-chloropurine (9) with diethyl [2-(2-chloroethoxy)ethyl]phosphonate (148) gave the diester149which was analogously converted toN⁶-substituted 2,6-diamino- 9-[2-(2-phosphonoethoxy)ethyl]purines151-153. Alkylation ofN⁶-substituted 2,6-diaminopurines with (R)-[(trityloxy)methyl]oxirane (155) followed by reaction of thus-obtained intermediates156with dimethylformamide dimethylacetal and condensation with diisopropyl [(tosyloxy)methyl]phosphonate (158) followed by deprotection of the intermediates159gaveN⁶-substituted 2,6-diamino-9-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]purines160-163. The highest cytostatic activityin vitrowas exhibited by the followingN⁶-derivatives of 2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine (PMEDAP): 2,2,2-trifluoroethyl (53), allyl (54), [(2-dimethylamino)ethyl] (68), cyclopropyl (75) and dimethyl (91). In CCRF-CEM cells, the cyclopropyl derivative75is deaminated to the guanine derivative PMEG (3) which is then converted to its diphosphate.

  N6-取代腺嘌呤和2,6-二氨基嘌呤衍生物9-[2-(磷酸甲氧基)-乙基]（PME）、9-[(R)-2-(磷酸甲氧基)丙基] [(R)-PMP] 和对映体(S)-PMP 系列通过初级或次级胺与6-氯-9-[2-(二异丙氧磷酰基)甲氧基]烷基}嘌呤（26-28）或2-氨基-6-氯-9-[2-(二异丙氧磷酰基)甲氧基]烷基}嘌呤（29-31）的反应合成，随后用溴化(三甲基)硅烷和水解处理二酯中间体32。二酯32也可通过N6-取代嘌呤与带有二异丙氧磷酰基的合成物23-25发生反应获得。2-氨基-6-氯嘌呤（9）与二乙基[2-(2-氯乙氧基)乙基]磷酸酯（148）的烷基化反应得到二酯149，类似地转化为N6-取代2,6-二氨基-9-[2-(2-磷酸乙氧基)乙基]嘌呤151-153。N6-取代2,6-二氨基嘌呤与(R)-[(三苄氧基)甲基]环氧乙烷（155）发生烷基化反应，随后用二甲基甲酰胺二甲基缩醛和与异丙基[(对甲苯磺酰氧基)甲基]磷酸酯（158）发生缩合反应，然后去保护中间体159得到N6-取代2,6-二氨基-9-[(S)-3-羟基-2-(磷酸甲氧基)丙基]嘌呤160-163。体外细胞毒活性最高的是以下2,6-二氨基-9-[2-(磷酸甲氧基)乙基]嘌呤（PMEDAP）的N6-衍生物：2,2,2-三氟乙基（53）、烯丙基（54）、[(2-二甲基氨基)乙基]（68）、环丙基（75）和二甲基（91）。在CCRF-CEM细胞中，环丙基衍生物75被脱氨基化为鸟嘌呤衍生物PMEG（3），然后转化为其二磷酸盐。
• Highly Enantioselective Synthesis of Chiral Cyclopropyl Nucleosides via Catalytic Asymmetric Intermolecular Cyclopropanation
  作者：Jian-Ping Li、Guo-Feng Zhao、Hai-Xia Wang、Ming-Sheng Xie、Gui-Rong Qu、Hai-Ming Guo

  DOI：10.1021/acs.orglett.7b03110

  日期：2017.12.15

  An efficient route to construct chiral cyclopropyl purine nucleoside analogues has been established via the catalytic asymmetric Michael-initiated ring-closure reactions of α-purine acrylates with α-bromo-carboxylic esters. Using (DHQD)2AQN as the catalyst, various chiral cyclopropyl purine nucleoside analogues with a chiral quaternary stereocenter were obtained in 72–98% yields, excellent diastereoselectivities

  通过α-嘌呤丙烯酸酯与α-溴代羧酸酯的催化不对称迈克尔引发的闭环反应，已经建立了构建手性环丙基嘌呤核苷类似物的有效途径。使用（DHQD）2AQN作为催化剂，可以获得具有手性四级立体中心的各种手性环丙基嘌呤核苷类似物，产率为72–98％，非对映选择性和93–97％ee。通过简单的官能团转化，获得具有羟甲基或羧基的多种手性环丙基嘌呤核苷。
• 6-Substituted purines as ROCK inhibitors with anti-metastatic activity
  作者：Jiří Voller、Lenka Zahajská、Lucie Plíhalová、Jana Jeřábková、David Burget、Andreea Csilla Pataki、Vladimír Kryštof、Marek Zatloukal、Jan Brábek、Daniel Rösel、Václav Mik、Martin Tkáč、Tomáš Pospíšil、Tomáš Gucký、Karel Doležal、Miroslav Strnad

  DOI：10.1016/j.bioorg.2019.103005

  日期：2019.9

  contractility, shape, motility, and invasion of cells. We explored the relationships between structure and anti-ROCK2 activity in a group of purine derivatives substituted at the C6 atom by piperidin-1-yl or azepan-1-yl groups. Structure-activity relationship (SAR) analyses suggested that anti-ROCK activity is retained, and may be further increased, by substitution of the parent compounds at the C2 atom or by expansion

  Rho相关的丝氨酸/苏氨酸激酶（ROCKs）是肌动蛋白细胞骨架的主要调节剂，可调节细胞的收缩性，形状，运动性和侵袭性。我们探索了在一组碳素原子上被哌啶-1-基或氮杂-1-基取代的嘌呤衍生物的结构与抗ROCK2活性之间的关系。结构活性关系（SAR）分析表明，通过在C2原子处取代母体化合物或通过扩展C6侧链，可以保留抗ROCK活性，并且可以进一步提高抗ROCK活性。这些ROCK抑制剂可以在细胞内达到有效浓度，这可以通过ROCK靶MLC磷酸化的减少以及抑制ROCK依赖的黑色素瘤细胞在胶原蛋白基质中的侵入来证明。